In-label, off-label prescription, efficacy and tolerability of dalbavancin: report from a National Registry.
Dalbavancin
In-label
Off-label
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
07 Feb 2024
07 Feb 2024
Historique:
received:
11
11
2023
accepted:
04
01
2024
medline:
7
2
2024
pubmed:
7
2
2024
entrez:
7
2
2024
Statut:
aheadofprint
Résumé
Although dalbavancin is currently approved for the treatment of ABSSIs, several studies suggest its efficacy and tolerance as long-term therapy for other off-label indications requiring prolonged intravenous antibiotic administration. We conducted a prospective nationwide study of dalbavancin use in real-life settings for both approved and off-label indications analysing for each case the clinical and microbiological characteristics of infection the efficacy and safety of treatments. During the study period (from December 2018 to July 2021), the ID specialists from 14 different centres enrolled 223 patients treated with dalbavancin [141 males (63%) and 82 females (37%); male/female ratio 1.72; mean age 59 (SD 17.2) years, (range 15-96). Most patients in the study population (136/223; 61.0%) came from community rather than health care facilities and most of them were visited in Infectious Diseases wards (93/223; 41.7%) and clinics (55/223; 24.7%) even though some patients were cured in other settings, such as surgery wards (18/223; 8.1%), orthopaedic wards (11/223; 4.9%), Emergency Rooms (7/223; 3.1%) and non-surgical other than ID wards (6/223; 2.7%). The most common ID diagnoses were osteomyelitis (44 cases/223; 19.7%; of which 29 acute and 15 chronic osteomyelitis), cellulitis (28/223; 12.5%), cutaneous abscess (23/223; 10.3%), orthopaedic prosthesis-associated infection (22/223; 9.9%), surgical site infection (20/223; 9.0%) and septic arthritis (15/223; 6.7%). In conclusion, by virtue of its PK/PD properties, dalbavancin represents a valuable option to daily in-hospital intravenous or outpatient antimicrobial regimens also for off-label indications requiring a long-term treatment of Gram-positive infections.
Identifiants
pubmed: 38324144
doi: 10.1007/s15010-024-02176-2
pii: 10.1007/s15010-024-02176-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Esposito S, Noviello S, Leone S. Dalbavancin for the treatment of acute bacterial skin and skin structure infections. Infez Med. 2015;23:313–7.
pubmed: 26700080
Barberán J, de la Cuerda A, Barberán LC (2021) Dalbavancin. Rev Esp Quimioter 34:26–28. https://doi.org/10.37201/req/s01.07.2021
Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–79. https://doi.org/10.1056/NEJMoa1310480 .
doi: 10.1056/NEJMoa1310480
pubmed: 24897082
Béraud G, Maupetit JC, Darras A, Vimont A, Blachier M. Dalbavancin in real life: economic impact of prescription timing in french hospitals. Infect Dis Ther. 2022;11:435–49. https://doi.org/10.1007/s40121-021-00577-6 .
doi: 10.1007/s40121-021-00577-6
pubmed: 34913137
Palmieri F, Alberici F, Deales A, et al. Early discharge of infectious disease patients: an opportunity or extra cost for the Italian Healthcare System? Infez Med. 2013;21:270–8.
pubmed: 24335457
Mazzitelli M, Gatti M, Scaglione V, et al. Off-label use of dalbavancin for sequential treatment of spondylodiscitis by methicillin-resistant staphylococcus aureus: a retrospective single-centre experience. Antibiotics (Basel). 2022;11:1377. https://doi.org/10.3390/antibiotics11101377 .
doi: 10.3390/antibiotics11101377
pubmed: 36290035
Hanses F, Dolff S, Trauth J, Seimetz M, Hagel S. A multicentre, prospective, and retrospective registry to characterize the use, effectiveness, and safety of dalbavancin in german clinical practice. Antibiotics (Basel). 2022;11:563. https://doi.org/10.3390/antibiotics11050563 .
doi: 10.3390/antibiotics11050563
pubmed: 35625206
Esposito S, Bassetti M, Concia E, De Simone G, De Rosa FG, Grossi P, et al. Diagnosis and management of skin and soft-tissue infections (SSTI) A literature review and consensus statement: an update. J Chemother. 2017;29:197–214.
doi: 10.1080/1120009X.2017.1311398
pubmed: 28378613
Miller LG, Eisenberg DF, Liu H, Chang CL, Wang Y, Luthra R, et al. Incidence of skin and soft tissue infections in ambulatory and inpatient settings, 2005–2010. BMC Infect Dis. 2015;15:362.
doi: 10.1186/s12879-015-1071-0
pubmed: 26293161
pmcid: 4546168
Esposito S, Noviello S, Leone S. Epidemiology and microbiology of skin and soft tissue infections. Curr Opin Infect Dis. 2016;29:109–15.
doi: 10.1097/QCO.0000000000000239
pubmed: 26779772
Edelsberg J, Taneja C, Zervos M, Haque N, Moore C, Reyes K, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerging Infect Dis. 2009;15:1516–8.
doi: 10.3201/eid1509.081228
Marra F, Patrick DM, Chong M, McKay R, Hoang L, Bowie WR. Population-based study of the increased incidence of skin and soft tissue infections and associated antimicrobial use. Antimicrob Agents Chemother. 2012;56:6243–9.
doi: 10.1128/AAC.00649-12
pubmed: 23006762
pmcid: 3497163
Pallin DJ, Espinola JA, Leung DY, Hooper DC, Camargo CA Jr. Epidemiology of dermatitis and skin infections in United States physicians’ offices, 1993–2005. Clin Infect Dis. 2009;49:901–7.
doi: 10.1086/605434
pubmed: 19663690
Esposito S, Pagliano P, De Simone G, et al. Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry. J Chemother. 2022;34:524–33. https://doi.org/10.1080/1120009X.2022.2075170 .
doi: 10.1080/1120009X.2022.2075170
pubmed: 35570742
Esposito S, De Simone G. Update on the main MDR pathogens: prevalence and treatment options. Infez Med. 2017;25:301–10.
pubmed: 29286008
Shahini Shams Abadi M, Nikokar I, Hoseini Alfatemi SM, Malekzadegan Y, Azizi A, Sedigh Ebrahim-Saraie H. Epidemiology of Panton-Valentine Leukocidin harbouring Staphylococcus aureus in cutaneous infections from Iran: a systematic review and meta-analysis. Infez Med. 2017;25:217–23.
Leone S, Noviello S, Boccia G, De Caro F, Esposito S. Methicillin-resistant Staphylococcus aureus infections: role of daptomycin/b-lactams combination. Infez Med. 2015;23:99–104.
pubmed: 26110289
Cascone C, Santagati M, Noviello S, Iannelli F, Esposito S, Pozzi G, et al. S. Macrolide-resistance genes in clinical isolates of Streptococcus pyogenes. Microb Drug Resist. 2002;8:129–32.
doi: 10.1089/107662902760190671
pubmed: 12118517
Esposito S, Bassetti M, Bonnet E, Bouza E, Chan M, De Simone G, et al. Hot topics in the diagnosis and management of skin and soft-tissue infections. Int J Antimicrob Agents. 2016;48:19–26.
doi: 10.1016/j.ijantimicag.2016.04.011
pubmed: 27216380
Esposito S, Noviello S, De Caro F, Boccia G. New insights into classification, epidemiology and microbiology of SSTIs, including diabetic foot infections. Infez Med. 2018;26:3–14.
pubmed: 29525792
US Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. Silver Spring (MD): US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2013. 23
Noviello S, Ianniello F, Esposito S. In vitro activity of LY333328 (oritavancin) against Gram-positive aerobic cocci and synergy with ciprofloxacin against enterococci J Antimicrob Chemother. 2001;48:283–286
Gatti M, Andreoni M, Pea F, Viale P. Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical need. Drug Design Dev Ther 2021;15:3349–78
Thomas G, Henao-Martínez AF, Franco-Paredes C, Chastain DB. Treatment of osteoarticular, cardiovascular, intravascular-catheter related and other complicated infections with dalbavancin and oritavancin: a systematic review. Int J Antimicrob Agents. 2020;56: 106069. https://doi.org/10.1016/j.ijantimicag.2020.106069 .
doi: 10.1016/j.ijantimicag.2020.106069
pubmed: 32603683
Monteagudo-Martínez N, Solís-García Del Pozo J, Nava E, Ikuta I. Acute Bacterial Skin and Skin-Structure Infections, efficacy of Dalbavancin: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2022;20:1477–89. https://doi.org/10.1080/14787210.2021.1828865 .
doi: 10.1080/14787210.2021.1828865
pubmed: 32981375
Bouza E, Valerio M, Soriano A, Morata L, García Carus E, Rodríguez-González C, Hidalgo-Tenorio MC, Plata A, Muñoz P, Vena A on behalf of the DALBUSE Study Group. Dalbavancin in the treatment of different gram-positive infections: a real-life experience. International Journal of Antimicrobial Agents 2018;51:571–77
Morata L, Aguado JM, Salavert M, Pasquau J, Míguez E, Muñoz P, Rosselló I, Almirant B. Dalbavancin in clinical practice in Spain: a 2 year retrospective study. JAC Antimicrob Resist. 2022. https://doi.org/10.1093/jacamr/dlac120 .
doi: 10.1093/jacamr/dlac120
pubmed: 36570687
pmcid: 9777743
Arrieta-Loitegui, Caro-Teller JM, Ortiz-Pérez S, López-Medrano F, San Juan-Garrido R, Ferrari-Piquero JM. Effectiveness, safety and cost analysis of dalbavancin in clinical practice. Eur J Hosp Pharm 2022;29:55–58. https://doi.org/10.1136/ejhpharm-2020-002315
Taylor K, Williamson J, Luther V, Stone T, Johnson J, Gruss Z, Russ-Friedman C, Ohl C, Beardsley J. Evaluating the use of dalbavancin for Off-label indications. Infect Dis Rep. 2022;14:266–72. https://doi.org/10.3390/idr14020032 .
doi: 10.3390/idr14020032
pubmed: 35447884
pmcid: 9026399
Lueking R, Wei W, Mang NS, Ortwine JK, Meisner J. evaluation of dalbavancin use on clinical outcomes, cost-savings, and adherence at a large safety net hospital. Microbiol Spect 1; 1
Dinha A, Durana C, Pavese P, Khatchatourianc L, Monnind B, Bleibtreue A, Denis E, Etienne C, Rouanes N, Mahieui R, Bouchandj F, Davidoa B, Lotte R, Cabaretl P, Camou F, Chavanet P, Assi A, Limonta S, Lechiche C, Riour R, Courjons J, Illes G, Lacassin-Beller F, Senneville E, On behalf of the Dalbavancin French Study Group. French national cohort of first use of dalbavancin: A high proportion of off-label use. Int J Antimicrob Agents. 2019;54:668–72.
doi: 10.1016/j.ijantimicag.2019.08.006
Ajaka L, Heil E, Schmalzle S. Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics. 2020;9:0700. https://doi.org/10.3390/antibiotics9100700 .
doi: 10.3390/antibiotics9100700
Bartoletti M, Mikusb E, Pascale R, Giannella M, Tedeschia S, Calvib S, Tentic E, Fabio Tumietto F, Pierluigi VP. Clinical experience with dalbavancin for the treatment of deep sternal wound infection. J Glob Antimicrob Res. 2019;18:195–8.
doi: 10.1016/j.jgar.2019.03.015
Baltin CT, Wulf C, Rongisch R, et al. Outpatient care concept and potential inpatient cost savings associated with the administration of dalbavancin - A real-world data and retrospective cost analysis. J Infect Public Health. 2023;16(6):955–63. https://doi.org/10.1016/j.jiph.2023.04.015 .
doi: 10.1016/j.jiph.2023.04.015
pubmed: 37099955
Pascale R, Maccaro A, Mikus E, et al. A retrospective multicentre study on dalbavancin effectiveness and cost-evaluation in sternotomic wound infection treatment: DALBA SWIT Study. J Glob Antimicrob Resist. 2022;30:390–4. https://doi.org/10.1016/j.jgar.2022.07.018 .
doi: 10.1016/j.jgar.2022.07.018
pubmed: 35878780